Status:
COMPLETED
Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction
Lead Sponsor:
University of Oxford
Collaborating Sponsors:
Sanofi
AstraZeneca
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of suspected acute MI w...
Detailed Description
Clopidogrel Despite considerable improvements in the emergency treatment of acute myocardial infarction (MI), including the use of aspirin, early mortality and morbidity remain high. The antiplatelet...
Eligibility Criteria
Inclusion
- Patients presenting with ST elevation, left bundle branch block or ST depression within 24 hours of the onset of the symptoms of suspected acute MI
Exclusion
- clear indications for, or contraindications to, any of the study treatments
Key Trial Info
Start Date :
July 1 1999
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
46000 Patients enrolled
Trial Details
Trial ID
NCT00222573
Start Date
July 1 1999
End Date
February 1 2005
Last Update
May 5 2006
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Cadiovascular diseases, Fuwai hospital, Chinese academy of medical sciences
Beijing, China, 100037
2
Clinical Trial Service Unit and Epidemiological Studies Unit
Oxford, United Kingdom, OX3 7LF